BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mordwinkin NM, Louie SG. Aralast: an α 1 -protease inhibitor for the treatment of α-antitrypsin deficiency. Expert Opinion on Pharmacotherapy 2007;8:2609-14. [DOI: 10.1517/14656566.8.15.2609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Parr DG, Lara B. Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature. Drug Des Devel Ther 2017;11:2149-62. [PMID: 28769553 DOI: 10.2147/DDDT.S105207] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Ashkenazi E, Baranovski BM, Shahaf G, Lewis EC. Pancreatic islet xenograft survival in mice is extended by a combination of alpha-1-antitrypsin and single-dose anti-CD4/CD8 therapy. PLoS One 2013;8:e63625. [PMID: 23717456 DOI: 10.1371/journal.pone.0063625] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
3 Marcet-palacios M, Ewen C, Pittman E, Duggan B, Carmine-simmen K, Fahlman RP, Bleackley RC. Design and characterization of a novel human Granzyme B inhibitor. Protein Engineering Design and Selection 2014;28:9-17. [DOI: 10.1093/protein/gzu052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
4 Bellacen K, Kalay N, Ozeri E, Shahaf G, Lewis EC. Revascularization of pancreatic islet allografts is enhanced by α-1-antitrypsin under anti-inflammatory conditions. Cell Transplant 2013;22:2119-33. [PMID: 23050776 DOI: 10.3727/096368912X657701] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
5 Chen H, Zheng D, Davids J, Bartee MY, Dai E, Liu L, Petrov L, Macaulay C, Thoburn R, Sobel E, Moyer R, McFadden G, Lucas A. Viral serpin therapeutics from concept to clinic. Methods Enzymol 2011;499:301-29. [PMID: 21683260 DOI: 10.1016/B978-0-12-386471-0.00015-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
6 Bari E, Ferrarotti I, Di Silvestre D, Grisoli P, Barzon V, Balderacchi A, Torre ML, Rossi R, Mauri P, Corsico AG, Perteghella S. Adipose Mesenchymal Extracellular Vesicles as Alpha-1-Antitrypsin Physiological Delivery Systems for Lung Regeneration. Cells 2019;8:E965. [PMID: 31450843 DOI: 10.3390/cells8090965] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
7 Casas F, Blanco I, Martínez MT, Bustamante A, Miravitlles M, Cadenas S, Hernández JM, Lázaro L, Rodríguez E, Rodríguez-frías F, Torres M, Lara B. Indications for Active Case Searches and Intravenous Alpha-1 Antitrypsin Treatment for Patients With Alpha-1 Antitrypsin Deficiency Chronic Pulmonary Obstructive Disease: An Update. Archivos de Bronconeumología (English Edition) 2015;51:185-92. [DOI: 10.1016/j.arbr.2014.12.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Wang J, Sun Z, Gou W, Adams DB, Cui W, Morgan KA, Strange C, Wang H. α-1 Antitrypsin Enhances Islet Engraftment by Suppression of Instant Blood-Mediated Inflammatory Reaction. Diabetes 2017;66:970-80. [PMID: 28069642 DOI: 10.2337/db16-1036] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
9 Shahaf G, Moser H, Ozeri E, Mizrahi M, Abecassis A, Lewis EC. α-1-antitrypsin gene delivery reduces inflammation, increases T-regulatory cell population size and prevents islet allograft rejection. Mol Med. 2011;17:1000-1011. [PMID: 21670848 DOI: 10.2119/molmed.2011.00145] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
10 Lewis EC. Expanding the clinical indications for α(1)-antitrypsin therapy. Mol Med 2012;18:957-70. [PMID: 22634722 DOI: 10.2119/molmed.2011.00196] [Cited by in Crossref: 102] [Cited by in F6Publishing: 97] [Article Influence: 11.3] [Reference Citation Analysis]
11 Casas F, Blanco I, Martínez MT, Bustamante A, Miravitlles M, Cadenas S, Hernández JM, Lázaro L, Rodríguez E, Rodríguez-frías F, Torres M, Lara B. Actualización sobre indicaciones de búsqueda activa de casos y tratamiento con alfa-1 antitripsina por vía intravenosa en pacientes con enfermedad pulmonar obstructiva crónica asociada a déficit de alfa-1 antitripsina. Archivos de Bronconeumología 2015;51:185-92. [DOI: 10.1016/j.arbres.2014.05.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 7.3] [Reference Citation Analysis]
12 Erhabor O, Adias TC. From whole blood to component therapy: the economic, supply/demand need for implementation of component therapy in sub-Saharan Africa. Transfus Clin Biol 2011;18:516-26. [PMID: 22037104 DOI: 10.1016/j.tracli.2011.06.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]